All In Biotech

Drug Trial Radar · NCT00979901

Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)

A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Seasonal Allergic Rhinitis--Spring Study

Last checked: Nov 19, 2026Latest source record: Feb 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,577 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,577

Actual

Start

Mar 2000

Primary completion

May 2000

Study completion May 2000

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Sep 18, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 15 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the ability of montelukast to improve the signs and symptoms of seasonal allergic rhinitis compared with loratadine and placebo.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • Comparator: montelukastDrug

    10 mg montelukast tablet given once daily at bedtime for 2 weeks

  • Comparator: loratadineDrug

    10 mg loratadine tablet given once daily at bedtime for 2 weeks

  • Comparator: placeboDrug

    placebo tablet given once daily at bedtime for 2 weeks

  • Comparator: montelukast/loratadineDrug

    montelukast 10-mg/loratadine 10-mg combination tablet taken orally once daily at bedtime for 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Daytime Nasal Symptoms Score Over 2 WeeksTime frame: Baseline and Week 2

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.